Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

TRACE: Tirapazamine-Radiation And Cisplatin Evaluation (TRACE)

This study has been completed.
Groupe Oncologie Radiotherapie Tete et Cou
Information provided by (Responsible Party):
Sanofi Identifier:
First received: September 13, 2005
Last updated: April 27, 2016
Last verified: April 2016
The trial will compare the efficacy and safety of concomitant chemoradiation with tirapazamine, cisplatin and radiation versus cisplatin and radiation.

Condition Intervention Phase
Head and Neck Squamous Cell Carcinoma
Drug: Tirapazamine
Drug: Cisplatin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase III Randomized Trial of Concomitant Radiation, Cisplatin, and Tirapazamine Versus Concomitant Radiation and Cisplatin in Patients With Advanced Head and Neck Cancer

Resource links provided by NLM:

Further study details as provided by Sanofi:

Primary Outcome Measures:
  • Overall survival [ Time Frame: Study period ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Failure Free Survival, Time To Loco-Regional Failure, Patterns of Failure [ Time Frame: Study period ] [ Designated as safety issue: No ]
  • Initial Response Rates at 2 Months After Completion of Chemoradiation Therapy, Final complete response (CR) Rate at Six Months After Completion of Therapy [ Time Frame: Study period ] [ Designated as safety issue: No ]
  • Change in QoL From Baseline, Percent of Patients Who Are Feeding Tube Dependent 12 Months After Completion of Therapy [ Time Frame: Study period ] [ Designated as safety issue: No ]
  • Toxicity and Safety [ Time Frame: Study period ] [ Designated as safety issue: Yes ]

Enrollment: 317
Study Start Date: April 2005
Study Completion Date: January 2008
Primary Completion Date: January 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Tirapazamine + Cisplatin Drug: Tirapazamine
in combination with cisplatin and concomitant radiation
Other Name: SR259075
Drug: Cisplatin
with concomitant radiation
Active Comparator: Cisplatin Drug: Cisplatin
with concomitant radiation


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Previously untreated squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx.
  • Stage III or IV disease (excluding T1N1, and T2N1 and metastatic disease).
  • Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.
  • Absolute neutrophil count at least 1.5 X 10^9/L, platelet count at least 100 X 10^9/L, and hemoglobin > 9g/dL.
  • Serum bilirubin < 1.25 times upper limit of normal (ULN) and aspartate aminotransferase (AST)/alanine transaminase (ALT) < 2.5 times ULN.
  • Calculated creatinine clearance (Cockcroft-Gault) > 55 mL/min.

Exclusion Criteria:

  • Metastatic Disease
  • Primary cancers of the nasal and paranasal cavities and of the nasopharynx
  • Significant intercurrent illness that will interfere with the Chemotherapy or Radiation Therapy during the trial
  • Symptomatic peripheral neuropathy > grade 2
  • Clinically significant hearing impairment
  • Significant cardiac disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00174837

  Show 17 Study Locations
Sponsors and Collaborators
Groupe Oncologie Radiotherapie Tete et Cou
Study Director: ICD CSD Sanofi
  More Information

Additional Information:
Responsible Party: Sanofi Identifier: NCT00174837     History of Changes
Other Study ID Numbers: EFC5512  SR259075 
Study First Received: September 13, 2005
Last Updated: April 27, 2016
Health Authority: United States: Food and Drug Administration

Keywords provided by Sanofi:
Head and Neck Cancer

Additional relevant MeSH terms:
Carcinoma, Squamous Cell
Head and Neck Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Squamous Cell
Neoplasms by Site
Antineoplastic Agents processed this record on October 21, 2016